Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Distinct cellular signatures in aplastic and intermittent phenotypes of immune effector cell-associated hematotoxicity.

Annals of hematology - 14 Apr 2026

Varon Ben, Grau Amir, Marco Noga Setter, Khatib Anwar, Levi Tsofia, Fineman Riva, Tzoran Inna, Mustafa Nivin, Zuckerman Tsila, Horowitz Netanel A, Lavi Noa, Novak Rostislav, Beyar-Katz Ofrat

Abstract excerpt

Bone marrow toxicity, or immune effector cell-associated hematotoxicity (ICAHT), is a notable complication of CAR T-cell therapy, characterized by persistent cytopenia’s and typically classified into three phenotypes: transient, intermittent and aplastic. This study aimed to characterize the bone marrow immune landscape associated with ICAHT phenotype( aplastic and intermittent) by analyzing patients with diffuse...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Anemia, Aplastic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Biological Products

Share to Bone Marrow

Share to Immunophenotyping

Share to Immunotherapy, Adoptive

Share to Lymphoma, Large B-Cell, Diffuse

Share to Phenotype

Source

Open in PubMed Open full text

Identifiers

PMID: 41979680
DOI: 10.1007/s00277-026-06993-3
PMCID: PMC13079477

Genes

CD34
CD33

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Distinct cellular signatures in aplastic and intermittent phenotypes of immune effector cell-associated hematotoxicity.PMID 41979680Read ↗

Immune effector cell-associated haematotoxicity after CAR T-cell therapy: from mechanism to managementSemantic proximity Read ↗

Prolonged Cytopenia with CAR-T Cell Therapy and Management RecommendationsSemantic proximity Read ↗

Autoimmune cytopenias in chronic lymphocytic leukemia: a concise review and treatment recommendations.Semantic proximity Read ↗

A distinct CAR-T cell phenotype mediates therapeutic response at limited doses.Semantic proximity Read ↗

Anti-CD7 allogeneic WU-CART-007 in patients with relapsed/refractory T-cell acute lymphoblastic leukemia/lymphoma: a phase 1/2 trialSemantic proximity Read ↗

Clonal hematopoiesis is associated with increased toxicity in large B-cell lymphoma patients treated with chimeric antigen receptor T cell therapySemantic proximity Read ↗

Hematopoiesis and immune reconstitution after CD19 directed chimeric antigen receptor T‐cells (CAR‐T): A comprehensive review on incidence, risk factors and current managementSemantic proximity Read ↗

Distinct cellular dynamics associated with response to CAR-T therapy for refractory B-cell lymphomaSemantic proximity Read ↗

Immunotherapy-Based Targeting and Elimination of Leukemic Stem Cells in AML and CMLSemantic proximity Read ↗

Immunogenomic Landscape of Hematological Malignancies.Semantic proximity Read ↗

Functional diversification and dynamics of CAR-T cells in patients with B-ALLSemantic proximity Read ↗

CAR19 therapy drives expansion of clonal hematopoiesis and associated cytopeniasSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.